| MAGGIC: Survival in patients with heart failure and preserved versus impaired left ventricular ejection fraction: an individual patient data meta-analysis | Clinical Trial Update III | Doughty, Robert - Kaye, David Martin
| Heart Failure (HF) | 5027-5028 |
| Fractional flow reserve versus angiography for guiding PCI | Clinical Trial Update III | Pijls, Nico HJ - Luescher, Thomas Felix
| Acute Coronary Syndromes (ACS) | 5025-5026 |
| SYNTAX - Optimal revascularization strategy in patients with three-vessel disease and/or left main disease: The 2 year outcomes of the SYNTAX Trial | Clinical Trial Update III | Kappetein A Pieter - Antunes Manuel J
| Acute Coronary Syndromes (ACS) | 5023-5024 |
| ATTEMPT: Clinical outcome after thrombectomy or standard angioplasty in patients with ST elevation myocardial infarction | Clinical Trial Update III | Burzotta, Francesco - Eeckhout, Eric
| Acute Coronary Syndromes (ACS) | 5021-5022 |
| REPLACE-2, ACUITY and HORIZONS trials results from a patient-level pooled analysis: the Impact of bleeding types on mortality after PCI | Clinical Trial Update III | Mehran, Roxana - Wijns, William
| Acute Coronary Syndromes (ACS) | 5017-5018 |
| MADIT-CRT Trial: Reduction in the risk of heart failure with preventive cardiac resynchronization therapy | Hot Line III | Moss, Arthur J - Breithardt, Guenter
| Heart Failure (HF) | 3592-3593 |
| PreSCD II: Prevention of Sudden Cardiac Death in Post Myocardial Infarction Patients: Risk Stratification, ICD Therapy Penetration and Related Longterm Outcome - Final Results of the German PreSCD II Registry | Hot Line III | Voeller, Heinz - Vardas, Panagiotis
| Sudden Cardiac Death and Resuscitation | 3590-3591 |
| European CRT Survey | Hot Line III | Bogale, Nigussie - Daubert, Jean-Claude
| Heart Failure (HF) | 3588-3589 |
| A randomized evaluation of irbesartan versus placebo in patients with Atrial Fibrillation (factorial design of ACTIVE Program) | Hot Line III | Yusuf, Salim - Brugada Terradellas, Josep
| Atrial Fibrillation | 3586-3587 |
| PROTECT Study: Effects of Rolofylline in Patients with Acute Heart Failure Syndrome and Renal Impairment | Hot Line III | Metra, Marco - Jessup, Mariell
| Heart Failure (HF) | 3584-3585 |
| KYOTO Heart Study: Effects of Valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events | Hot Line III | Matsubara, Hiroaki - Ruschitzka Frank
| Cardiovascular Disease Prevention - Risk Assessment and Management | 3582-3583 |
| RECORD: Effect of rosiglitazone on coronary events in the RECORD study | Clinical Trial Update II | McMurray, John - Charbonnel, Bernard
| Cardiovascular Disease Prevention - Risk Assessment and Management | 2796-2697 |
| Copenhagen City Heart: Nonfasting cholesterol and triglycerides, myocardial infarction, and early death | Clinical Trial Update II | Nordestgaard, Borge - Fuster, Valentin
| Acute Coronary Syndromes (ACS) | 2704-2705 |
| REACH: International impact of atherothrombotic vascular disease and events - 3-year data from the REACH Registry | Clinical Trial Update II | Alberts, Mark - Danchin, Nicolas
| Cardiovascular Disease Prevention - Risk Assessment and Management | 2702-2703 |
| JUPITER: Randomized evidence on Rosuvastatin for primary prevention in individuals 70 years of age or older | Clinical Trial Update II | Glynn, Robert - Steg, Philippe Gabriel
| Cardiovascular Disease Prevention - Risk Assessment and Management | 2700-2701 |
| BEAUTIFUL: Effect of ivabradine on cardiovascular outcomes in patients with stable CAD and LV dysfunction with limiting angina: a subgroup analysis of the BEAUTIFUL trial | Clinical Trial Update II | Ferrari, Roberto - Heusch, Gerd
| Chronic Ischaemic Heart Disease (IHD) | 2698-2699 |
| TRITON-TIMI 38 Trial results: The risk of cardiovascular event for patients treated with clopidogrel or prasugrel in combination with a Proton Pump Inhibitor | Clinical Trial Update II | O'Donoghue, Michelle - Huber, Kurt
| Acute Coronary Syndromes (ACS) | 2694-2695 |
| ISAR-TEST-4 study: Randomized trial of 3-limus agent-eluting stents with biodegradable or permanent polymer coating | Hot Line II | Mehilli, Julinda - Kugelmass, Aaron
| Acute Coronary Syndromes (ACS) | 1852-1853 |
| PRAGUE-7 Study: Routine upfront abciximab versus standard peri-procedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock | Hot Line II | Widimsky, Petr - Lafont, Antoine
| Acute Coronary Syndromes (ACS) | 1850-1851 |
| TRIANA Study: Primary angioplasty versus fibrinolysis in the very elderly | Hot Line II | Bueno, Hector - Dudek, Dariusz
| Acute Coronary Syndromes (ACS) | 1848-1849 |
| GRACE left main study: unprotected left main revascularization in patients with acute coronary syndromes | Hot Line II | Montalescot, Gilles - Hamm, Christian
| Acute Coronary Syndromes (ACS) | 1846-1847 |
| NORDISTEMI study: Immediate angioplasty versus ischemia-guided management after thrombolysis for ST-segment elevation myocardial infarction in areas with very long transfers | Hot Line II | Halvorsen, Sigrun - Verheugt, Freek
| Acute Coronary Syndromes (ACS) | 1844-1845 |
| SEPIA-ACS1 TIMI 42 Results: Clinical Efficacy and Safety of Otamixaban, an Intravenous, Selective Factor Xa Inhibitor for the Treatment of Non-ST-Elevation Acute Coronary Syndromes | Hot Line I | Sabatine, Marc - White, Harvey
| Acute Coronary Syndromes (ACS) | 183-184 |
| RE-LY: A randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke | Hot Line I | Connolly, Stuart J - Camm, John
| Atrial Fibrillation | 181-182 |
| PLATO: Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results of the PLATelet inhibition and patient Outcomes (PLATO) trial | Hot Line I | Wallentin, Lars - Kristensen, Steen Dalby
| Acute Coronary Syndromes (ACS) | 179-180 |
| CURRENT OASIS 7 Trial Results: A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes | Hot Line I | Mehta, Shamir R - Van de Werf, Frans
| Acute Coronary Syndromes (ACS) | 177-178 |
| AAA: Randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis | Hot Line I | Fowkes, Gerry - Patrono, Carlo
| Cardiovascular Disease Prevention - Risk Assessment and Management | 175-176 |
| REVERSE: Cardiac Resynchronization Therapy Induces Major Structural and Functional Reverse Remodeling In Mild Heart Failure. 24 month results of the REVERSE trial | Clinical Trial Update I | Ghio, Stephano - Cleland, John
| Heart Failure (HF) | 1035-1036 |
| PROSPECT: Characteristics of patients enrolled in the Predictors of Response to CRT (PROSPECT) trial - comparison of subgroups according to extent of LV reverse remodeling | Clinical Trial Update I | van Bommel, Rutger - Linde, Cecilia
| Heart Failure (HF) | 1033-1034 |
| RECORD: Heart failure events assessment in the Rosiglitazone Evaluation for Cardiac Outcomes and Regulation of Glycaemia in Diabetes | Clinical Trial Update I | Komajda, Michel - Dickstein, Kenneth
| Heart Failure (HF) | 1031-1032 |
| GISSI-HF trial: ancillary results - effects of rosuvastatin on atrial fibrillation occurrence | Clinical Trial Update I | Maggioni, Aldo Pietro - Crijns Harry
| Atrial Fibrillation | 1029-1030 |
| BEAUTIFUL: The impact of achieved heart rate and reduction in heart rate on cardiovascular outcomes - an analysis of the Ivabradine arm of the BEAUTIFUL trial | Clinical Trial Update I | Fox, Kim - Boehm, Michael
| Chronic Ischaemic Heart Disease (IHD) | 1027-1028 |
| B-CONVINCED: Beta-blocker CONtinuation Versus INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode | Clinical Trial Update I | Jondeau, Guillaume - Swedberg, Karl
| Heart Failure (HF) | 1025-1026 |